How Pharma Is Investing In Healthcare’s Future

The Biopharma sector has never been more conscious of the disruptive potential of digital health. For several years, industry leaders have taken increasingly proactive approaches to innovation, leveraging investment, partnerships and acquisitions to bolster their digital strategies, to create more personalised patient experiences, and to enhance traditional pharma product lines. Against this backdrop, and that of COVID-19, which has shown as never before the urgency of healthcare transformation, how are the pharma’s investment leaders approaching digital health innovation, and how can innovators work begin to work with pharma? A panel of digital health investment experts from the biopharma sector dive into this essential issue.


• The bottom line - digital health’s disruptive potential in biopharma
• Partnership vs acquisition: long term strategies when investing in innovation
• How and why COVID-19 has boosted investment levels

Moderator: Lala Gregorek, Analyst, Trinity Delta
Rana Lonnen, Head of Search and Evaluation, Strategic Capital, Novartis
Bruce Meadows, Head of Investments, Takeda Digital Ventures
Lara Koole, Founder and Partner, Philips Ventures

The LSX channel features sessions from LSX events, where our mission is to connect senior #biotech, #medtech & #healthtech executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.

Subscribe to our channel for more videos.